Given that genomic instability appears to contribute to the frequent rapid relapses seen in patients with AML with FLT3-ITD [4, 19], incorporation of pan-Pim inhibitors into chemotherapy regimens may be beneficial not only for chemosensitization, but also to decrease genomic instability, and decreased genomic instability may have clinical benefit. Here, PIM1 is linked to acute myeloid leukemia.